Some RA treatments up second nonmelanoma skin cancer risk

Some RA treatments up second nonmelanoma skin cancer risk
(HealthDay)—For patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) with prior nonmelanoma skin cancer (NMSC), the risk of second NMSC varies with different treatments, according to a study published online Oct. 28 in JAMA Dermatology.

Frank I. Scott, M.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the relative hazard of a second NMSC in with RA or IBD who use methotrexate, anti-tumor necrosis factor (TNF) therapy, or thiopurines. Data were included for 6,841 patients with RA and 2,788 with IBD in a .

The researchers found that the incidence rates of a second NMSC were 58.2 and 58.9 per 1,000 person-years in patients with RA and IBD, respectively. Methotrexate used in conjunction with other medications correlated with increased risk of a second NMSC among patients with RA (hazard ratio, 1.60). The risk of a second NMSC increased with one year or more of methotrexate use, after adjustment for other medications (hazard ratio, 1.24). The addition of anti-TNF drugs versus alone correlated with increased risk of NMSC (hazard ratio, 1.49). There was no correlation for abatacept and rituximab with increased NMSC risk. For IBD, the hazard ratios for one year or more of thiopurine and anti-TNF were nonsignificant.

"These data can be used to guide therapeutic decisions in patients with prior NMSC," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

Study compares hospitalized infection risk for biologics in RA

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: JAMA Dermatology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Some RA treatments up second nonmelanoma skin cancer risk (2015, October 29) retrieved 20 June 2019 from https://medicalxpress.com/news/2015-10-ra-treatments-nonmelanoma-skin-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more